Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE: To quantify levels of subvisible particles and protein aggregates in repackaged bevacizumab obtained from compounding pharmacies, as well as in samples of bevacizumab and ranibizumab tested in controlled laboratory experiments. METHODS: Repackaged bevacizumab was purchased from four external compounding pharmacies. For controlled laboratory studies, bevacizumab and placebo were drawn into plastic syringes and incubated at -20°C, 4°C, and room temperature (with and without exposure to light) for 12 weeks. In addition, mechanical shock occurring during shipping was mimicked with syringes containing bevacizumab. Particle counts and size distributions were quantified by particle characterization technology. Levels of monomer and soluble aggregates of bevacizumab were determined with size-exclusion high-performance liquid chromatography (SE-HPLC). RESULTS: Repackaged bevacizumab from the compounding pharmacies had a wide range of particle counts (89,006 ± 56,406 to 602,062 ± 18,349/mL). Bevacizumab sampled directly from the original glass vial had particle counts of 63,839 ± 349/mL. There was up to a 10% monomer loss in the repackaged bevacizumab. Laboratory samples of repackaged bevacizumab and placebo had initial particle counts, respectively, of 283,675 ± 60,494/mL and 492,314 ± 389,361/mL. Freeze-thawing of both bevacizumab and placebo samples led to >1.2 million particles/mL. In all repackaged samples, most of the particles were due to silicone oil. SE-HPLC showed no significant differences for repackaged samples incubated in the laboratory under various conditions, compared with bevacizumab directly from vial. However, repeated freeze-thawing caused a more than 10% monomer loss. CONCLUSIONS: Bevacizumab repackaged in plastic syringes could contain protein aggregates and is contaminated by silicone oil microdroplets. Freeze-thawing or other mishandling can further increase levels of particle contaminants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Exposure to light has been shown to increase particulate count by 2.5 times [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protein aggregates can form under a variety of circumstances prior to intravitreal injection of the drug and they can be further induced by SO release from syringes [57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various factors can contribute to SO release from the inner cylinder wall, protein denaturing, or both [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Freeze-thawing that may occur during shipping has been demonstrated to significantly increase SO microdroplet release in bevacizumab solution, along with increased protein particle levels [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Many processes involved in the shipping, handling and storage of anti-VEGF medications and syringes can contribute to SO release and protein aggregation [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution
Thirumangalathu, R., Krishnan, S., Ricci, M. S., Brems, D. N., Randolph, T. W., & Carpenter, J. F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21719 · Cited by 294
Self-citationSustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
Good, T. J., Kimura, A. E., Mandava, N., & Kahook, M. Y. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.180729 · Cited by 245
Self-citationSilicone oil induced glaucoma: A review
Ichhpujani, P., Jindal, A., & Jay Katz, L. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1155-x · Cited by 204
Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions
Ludwig, D. B., Carpenter, J. F., Hamel, J., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21982 · Cited by 137
Self-citationHIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
Kahook, M. Y., Liu, L., Ruzycki, P. A., Mandava, N., Carpenter, J. F., Petrash, J. M., & Ammar, D. A. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cea · Cited by 130
Self-citationPersisent ocular hypertension following intravitreal ranibizumab
Bakri, S. J., McCannel, C. A., Edwards, A. O., & Moshfeghi, D. M. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0819-2 · Cited by 129
Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections
Kahook, M. Y., KIMURA, A. E., Wong, L. J., Ammar, D. A., Maycotte, M. A., & Mandava, N. (2009) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20090430-12 · Cited by 127
Self-citationSubramanian, M. L., Abedi, G., Ness, S. D., Ahmed, E., Fenberg, M. J., Daly, M. K., Houranieh, A. M., & Feinberg, E. B. (2010) · Eye · doi:10.1038/eye.2010.147 · Cited by 105
Research works printed but not linked: 2
- [15]15. Sharma DK Oma P, Krishnan S. Silicone microdroplets in protein formulations detection and enumeration. Pharm Technol 2009;33: 74-79.
- [18]18. Crampton S, Ricci M. Development and Application of a Fourier Transform Infrared (FTIR) Spectroscopy Method to Quantify Silicone Oil Extracted from Syringes. AAPS National BioTechnology. Conference. San Francisco: The American Association of Pharmaceutical Scientists; 2010.
Cited by
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Issues arise because bevacizumab has not been formulated for ocular use (Liu et al., 2011a; Ng et al., 2012; Palmer et al., 2013).”
Protein Aggregation and Particle Formation in Prefilled Glass Syringes
Gerhardt, A., Mcgraw, N. R., Schwartz, D. K., Bee, J. S., Carpenter, J. F., & Randolph, T. W. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23973 · Cited by 197
Self-citationDwivedi, M., Blech, M., Presser, I., & Garidel, P. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.008 · Cited by 188
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187
“As silicone oil forms a hydrophobic surface at the glass barrel-toliquid interface, protein degradation and aggregation might happen, as described in the literature [26,37,36,32,51].”
BackgroundAnderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Rojko, J. L., Evans, M. G., Price, S. A., Han, B., Waine, G. J., DeWitte, M., Haynes, J. A., Freimark, B. D., Martin, P. L., Raymond, J. T., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314526475 · Cited by 157
“Igs, including mAbs, can aggregate during production, formulation, compounding, or by exposure to silicone oil in plastic syringes (Kahook et al. 2010; Liu et al. 2011; Thirumangalathu et al. 2009).”
BackgroundPreclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
Meyer, C. H., & Holz, F. G. (2011) · Eye · doi:10.1038/eye.2011.66 · Cited by 143
Hoang, Q. V., Mendonça, L. S., Torre, K. E. D., Jung, J. J., Tsuang, A. J., & Freund, K. B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.08.011 · Cited by 140
Weinbuch, D., Zölls, S., Wiggenhorn, M., Frieß, W., Winter, G., Jiskoot, W., & Hawe, A. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23552 · Cited by 133
Strehl, R., Rombach‐Riegraf, V., Diez, M., Egodage, K. L., Bluemel, M., Jeschke, M., & Koulov, A. V. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0590-7 · Cited by 121
“Computer analysis of these particle images does not only allow accurate counting, but also classification of the particles based on their morphology (4,5).”
Nejadnik, M. R., Randolph, T. W., Volkin, D. B., Schöneich, C., Carpenter, J. F., Crommelin, D. J. A., & Jiskoot, W. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.04.005 · Cited by 119
Self-citationProtein Particulate Detection Issues in Biotherapeutics Development—Current Status
Das, T. K. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9793-4 · Cited by 124
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Self-citationRuiz, A. J. C., Boushehri, M. A. S., Phan, T., Carle, S., Garidel, P., Buske, J., & Lamprecht, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122575 · Cited by 108
Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab
Tyagi, P., Barros, M., Stansbury, J. W., & Kompella, U. B. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300716t · Cited by 103
Hoang, Q. V., Tsuang, A. J., Gelman, R., Mendonça, L. S., Torre, K. E. D., Jung, J. J., & Freund, K. B. (2012) · Retina · doi:10.1097/iae.0b013e318261a6f7 · Cited by 101
“Others have theorized that silicone oil used to lubricate the components of syringes or the accumulation of protein aggregates may play a role in these sustained IOP elevations.(22,23)”
BackgroundResultMathalone, N., Arodi-Golan, A., Sar, S., Wolfson, Y., Shalem, M., Lavi, I., & Geyer, O. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-1981-0 · Cited by 101
“It was hypothesized that repackaging of the drug in plastic syringes and long-term storage may lead to aggregation of proteins and/or nonprotein materials such as silicone oil from the syringes, which can induce mechanical obstruction to aqueous outflow [13, 14].”
BackgroundCourtois, F., Agrawal, N. J., Lauer, T. M., & Trout, B. L. (2015) · mAbs · doi:10.1080/19420862.2015.1112477 · Cited by 101
Avastin Doesn't Blind People, People Blind People
Gonzalez, S., Rosenfeld, P. J., Stewart, M. W., Brown, J., & Murphy, S. P. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.11.023 · Cited by 99
Bakri, S. J., Moshfeghi, D. M., Francom, S., Rundle, A. C., Reshef, D. S., Lee, P. P., Schaeffer, C., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.029 · Cited by 97
The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma
Hoguet, A. S., Chen, P. P., Junk, A. K., Mruthyunjaya, P., Nouri‐Mahdavi, K., Radhakrishnan, S., Takusagawa, H. L., & Chen, T. C. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.019 · Cited by 92
Moss, A. C., Brinks, V., & Carpenter, J. F. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12507 · Cited by 91
“2 million particles/mL) in a biologic drug in one study.(50) Another cause of accidental freezing”
BackgroundInfluentialSelf-citationBracha, P., Moore, N. A., Ciulla, T. A., WuDunn, D., & Cantor, L. B. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.08.008 · Cited by 86
Levin, A. M., Chaya, C. J., Kahook, M. Y., & Wirostko, B. M. (2021) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001894 · Cited by 90
Self-citationGross-Rother, J., Blech, M., Preis, E., Bakowsky, U., & Garidel, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111112 · Cited by 88
“Several studies investigated the effects of silicon oil in protein formulations, such as the risk of aggregation initiation and immunogenic risks [39,40,133,134].”
BackgroundDedania, V. S., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000520 · Cited by 84
Wehrli, S., Tawse, K. L., Levin, M. H., Zaidi, A. M., Pistilli, M., & Brucker, A. J. (2012) · Retina · doi:10.1097/iae.0b013e31823f0c95 · Cited by 76
Aflibercept-Related Sterile Intraocular Inflammation Outcomes
Greenberg, J. P., Belin, P., Butler, J., Feiler, D., Mueller, C., Tye, A., Friedlander, S. M., Emerson, G. G., & Ferrone, P. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.04.006 · Cited by 69
CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Today’s and Future Treatments
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Mandava, N., & Quiroz-Mercado, H. (2012) · Retina · doi:10.1097/iae.0b013e318271f265 · Cited by 76
Self-citationWerk, T., Volkin, D. B., & Mahler, H. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.12.014 · Cited by 66
VEGF as a Paracrine Regulator of Conventional Outflow Facility
Reina‐Torres, E., Wen, J. C., Liu, K. C., Li, G., Sherwood, J. M., Chang, J. Y. H., Challa, P., Flügel‐Koch, C., Stamer, W. D., Allingham, R. R., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20779 · Cited by 62
Khurana, R. N., Chang, L. K., & Porco, T. C. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.1815 · Cited by 61
Yannuzzi, N. A., PATEL, S. N., Bhavsar, K. V., Sugiguchi, F., & Freund, K. B. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.04.029 · Cited by 59
Wen, J. C., Reina‐Torres, E., Sherwood, J. M., Challa, P., Liu, K. C., Li, G., Chang, J. Y. H., Cousins, S. W., Schuman, S. G., Mettu, P. S., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20786 · Cited by 59
Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections
Meyer, C. H., Krohne, T. U., Charbel Issa, P., Liu, Z., & Holz, F. G. (2016) · Developments in Ophthalmology · doi:10.1159/000431143 · Cited by 57
Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection
Yannuzzi, N. A., Klufas, M. A., Quach, L., Beatty, L. M., Kaminsky, S. M., Crystal, R. G., D’Amico, D. J., & Kiss, S. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3591 · Cited by 60
Issues with Intravitreal Administration of Anti-VEGF Drugs
Schargus, M., & Фрингс, А. (2020) · Clinical ophthalmology · doi:10.2147/opth.s207978 · Cited by 62
Injectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 61
“Aggregation can occur due to shear and filling steps, multiple freeze–thaw cycles, compounding and mechanical shock [29,30].”
BackgroundPaul, M., Vieillard, V., Roumi, E., Cauvin, A., Despiau, M.-C., Laurent, M., & Astier, A. (2012) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2012.03.006 · Cited by 55
“Consequently, these objects ere identified as silicone oil microdroplets, as previously escribed by several authors [12,13].”
BackgroundFreezing-Induced Perturbation of Tertiary Structure of a Monoclonal Antibody
Liu, L., Braun, L. J., Wang, W., Randolph, T. W., & Carpenter, J. F. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24013 · Cited by 53
Self-citationDevelopment of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Keane, P. A., & Sadda, S. R. (2012) · Journal of Ophthalmology · doi:10.1155/2012/483034 · Cited by 51
“Studies have demonstrated differences in bevacizumab concentration and the presence of particulate contaminants following this process, emphasizing the need for implementation of optimal protocols when compounding pharmacies prepare this drug for intravitreal use [58, 68].”
BackgroundUchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49
Quality of bevacizumab compounded for intravitreal administration
Palmer, J. M., Amoaku, W. M. K., & Kamali, F. (2013) · Eye · doi:10.1038/eye.2013.139 · Cited by 49
The link between intravitreal antivascular endothelial growth factor injections and glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000036 · Cited by 46
“the same group showed that samples of repackaged bevacizumab from compounding pharmacies had a wide range of particle counts and were contaminated by silicone droplets, with loss of up to 10% of bevacizumab monomers [59].”
BackgroundSelf-citationStorage stability of bevacizumab in polycarbonate and polypropylene syringes
Khalili, H., Sharma, G., Froome, A., Khaw, P. T., & Brocchini, S. (2015) · Eye · doi:10.1038/eye.2015.28 · Cited by 45
Aref, A. A. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834ff41d · Cited by 44
Kampougeris, G., Spyropoulos, D., & Mitropoulou, A. (2013) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10008-1132 · Cited by 43
LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN)
Avery, R. L., Castellarin, A. A., Dhoot, D. S., Pieramici, D. J., Nasir, M. A., Steinle, N. C., Avery, L. P., & Gordon, G. M. (2019) · RETINAL Cases & Brief Reports · doi:10.1097/icb.0000000000000570 · Cited by 43
Long-term intraocular pressure changes after intravitreal injection of bevacizumab
Baek, S. U., Park, I. W., & Suh, W. (2016) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2015.1124886 · Cited by 43
Sarkar, A., Junnuthula, V., & Dyawanapelly, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910594 · Cited by 40
Funke, S., Matilainen, J., Nalenz, H., Bechtold-Peters, K., Mahler, H., & Frieß, W. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.08.031 · Cited by 41
Uveitis Following Intravitreal Bevacizumab: A Non-Infectious Cluster
Kay, C. N., Tarantola, R. M., Gehrs, K. M., Folk, J. C., Mahajan, V. B., Boldt, H. C., Syed, N. A., & Russell, S. R. (2011) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/15428877-20110603-04 · Cited by 37
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570340 · Cited by 35
“These aggregates can form during production or formulation of a biotherapeutic (Leach et al. 2014; Liu et al. 2011).”
BackgroundKaja, S., Hilgenberg, J. D., Everett, E. M., Olitsky, S. E., Gossage, J., & Koulen, P. (2011) · Human Antibodies · doi:10.3233/hab-2011-0244 · Cited by 35
“One recent study addressed the effect of storage of Avastin TM in syringes and the contamination by silicone oil microdroplets, however, did not investigate degradation and/or aggregation [16].”
Preclinical challenges for developing long acting intravitreal medicines
Awwad, S., Henein, C., Ibeanu, N., Khaw, P. T., & Brocchini, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.05.005 · Cited by 35
Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents
Singh, R. S., & Kim, J. E. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0031-2 · Cited by 33
“Leaching of silicone oil microdroplets may occur in syringes, especially with freeze-thaw cycles and rough mechanical handling, and this has been suggested as another potential mechanism of post-injection sustained elevated IOP [35, 36].”
BackgroundSkalicky, S. E., Ho, I., Agar, A., & Bank, A. (2012) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20120618-01 · Cited by 32
Frazier, K. S., & Obert, L. (2018) · Toxicologic Pathology · doi:10.1177/0192623318789399 · Cited by 34
Abedi, G., Adelman, R. A., & Salim, S. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.771195 · Cited by 32
“Li et al.(8) obtained repackaged bevacizumab from four external compounding pharmacies and looked at several factors, such as incubation at different temperatures and mechanical shock.”
BackgroundUveitis Following Intravitreal Injections of Faricimab: A Case Report
Palmieri, F., Younis, S., Bedan, A. H., & Fabozzi, L. (2023) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2023.2293925 · Cited by 31
Noninfectious Intraocular Inflammation After Intravitreal Aflibercept
Binder, K. E., Bleidißel, N., Issa, P. C., Maier, M. M., & Coulibaly, L. M. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0969 · Cited by 31
Menke, M. N., Salam, A., Framme, C., & Wolf, S. (2013) · Ophthalmologica · doi:10.1159/000346397 · Cited by 29
Changes in intraocular pressure in study and fellow eyes in the IVAN trial
Foss, A. J. E., Scott, L. J., Rogers, C. A., Reeves, B. C., Ghanchi, F. D., Gibson, J. M., & Chakravarthy, U. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307595 · Cited by 29
Agard, É., El-Chehab, H., Ract-Madoux, G., Russo, A., Lagenaite, C., & Dot, C. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.11.004 · Cited by 28
Perera, H. A. G., Lu, T., Fu, L., Zhang, J., & Chen, Z. (2019) · Langmuir · doi:10.1021/acs.langmuir.9b02768 · Cited by 26
Schargus, M., Werner, B. P., Geerling, G., & Winter, G. (2017) · Retina · doi:10.1097/iae.0000000000001809 · Cited by 25
Mechanical Shock During Shipping of Medications: The Roles of Packaging and Transportation Vendors
Dill, S., Brees, K., Stahly, A., Cheng, E. C., Carpenter, J. P., & Caplan, L. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.050 · Cited by 25
Self-citationTHE EFFECTS OF AFLIBERCEPT ON THE VIABILITY AND METABOLISM OF OCULAR CELLS IN VITRO
Ammar, D. A., Mandava, N., & Kahook, M. Y. (2012) · Retina · doi:10.1097/iae.0b013e31827b646d · Cited by 25
“Our recent work has shown that some repackaged bevacizumab contains high–molecular weight aggregates as well as silicone oil microdroplets that may contribute to the elevation of intraocular pressure.(29,30) The potential for bevacizumab antibody:antigen aggregates(31) to trigger inflammation in the trabecular meshwor…”
BackgroundSelf-citationEntezari, M., Karimi, S., Ahmadieh, H., Mahmoudi, A. H., Parhizgar, H., & Yaseri, M. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3426-7 · Cited by 29
Emerson, G. G. (2017) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126417735963 · Cited by 24
Hoang, Q. V., Jung, J. J., Mrejen, S., & Freund, K. B. (2013) · Retina · doi:10.1097/iae.0000000000000039 · Cited by 24
“Others have theorized that silicone oil used to lubricate the components of syringes or the accumulation of protein aggregates may play a role in these sustained IOP elevations.(23,24) Although these may be possible mechanisms, these are less likely given that there is no increase in risk for sustained IOP in those wh…”
BackgroundSignorello, L., Pucciarelli, S., Bonacucina, G., Polzonetti, V., Cespi, M., Perinelli, D. R., Palmieri, G. F., Pettinari, R., Pettinari, C., Fiorentini, G., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140619120834 · Cited by 28
“Although in the literature there are several studies on the stability of repackaged Bevacizumab [26, 27], this study relates directly to three different factors: drug concentration, microbial contamination, and physico-chemical stability.”
BackgroundAcute sterile endophthalmitis following intravitreal bevacizumab: case series
Vélez-Montoya, R., Ortega-Larrocea, X., Orozco‐Hernández, A., Sánchez-Bermúdez, G., Morales-Cantón, V., & García‐Aguirre, G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s66230 · Cited by 25
“In the past few years, there has been an increasing number of reports of high intraocular pressure and inflammation after intravitreal use of bevacizumab.(13,28) The present case series describes the clinical presentation and outcomes of ten consecutive cases that occurred after intravitreal administration of bevacizu…”
Bai, S., Landsman, P., Spencer, A., DeCollibus, D. P., Vega, F., Temel, D. B., Houde, D. J., Henderson, O., & Brader, M. L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.012 · Cited by 23
Kim, S., Fajnkuchen, F., Sarda, V., Qu, L., Bodaghi, B., & Giocanti‐Auregan, A. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3782-y · Cited by 24
“This IOP elevation could be due to numerous factors according to the literature: direct inhibitory effect of anti-VEGF on the cells of the trabecular meshwork [42], obstructive toxic effect of silicone oil micro-droplets and protein aggregates contained in the syringes during storage [43], trabecular lesion due to vol…”
Kim, N. A., Kim, D. J., & Jeong, S. H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119704 · Cited by 24
Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model
Gal‐Or, O., Dotan, A., Dachbash, M., Tal, K., Nisgav, Y., Weinberger, D., Ehrlich, R., & Livnat, T. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.02.006 · Cited by 23
Wang, M., Li, Y., Srinivasan, P., Hu, Z., Wang, R., Saragih, A., Repka, M. A., & Murthy, S. N. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1184-z · Cited by 22
Thompson, J. T. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.07.021 · Cited by 22
Agra, L. L. D. M., Sverstad, A., Chagas, T. A., de Araújo, R. H. C., de Oliveira, L. G., Kristianslund, O., Petrovski, G., Maia, M., Moe, M. C., Jørstad, Ø. K., et al. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.06.003 · Cited by 21
Cohen, J. R., Brych, S. R., Prabhu, S., Bi, V., Elbaradei, A., Tokuda, J. M., Xiang, C. D., Hokom, M. M., Cui, X., Ly, C. G., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03678-2 · Cited by 23
“Proteinaceous particles, that may be silicone oil-induced, can also arise in the clinical setting as a result of handing with a syringe or infusion through a catheter [83, 106, 112].”
PARTICULATE MATTER FROM SYRINGES USED FOR INTRAVITREAL INJECTIONS
Dounce, S. M., Laskina, O., & Goldberg, R. A. (2020) · Retina · doi:10.1097/iae.0000000000002947 · Cited by 21
Maruyama-Inoue, M., Inoue, T., Mohamed, S., Kitajima, Y., Ikeda, S., Ito, A., & Kadonosono, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-91832-w · Cited by 20
da Cruz, N. F. S., Polizelli, M. U., Muralha, F. P., de Morais, C. N. L., Silva, O. M., Maia, M., Melo, G. B., & Farah, M. E. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-022-00387-z · Cited by 20
Olea, J. L., Gómez-Resa, M., Peris, M. C., & Aragón, J. A. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672118823133 · Cited by 20
“30(4) 774 –779 © The Author(s) 2019 Article reuse guidelines: sagepub.”
InfluentialEvaluation of post-production handling practices of monoclonal antibodies throughout the world
Fayek, R., Soleyman, M., Jiskoot, W., & Crul, M. (2021) · European Journal of Oncology Pharmacy · doi:10.1097/op9.0000000000000031 · Cited by 19
Vitharana, S., Stillahn, J. M., Katayama, D. S., Henry, C. S., & Manning, M. C. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.003 · Cited by 20
Lyophilization of High-Concentration Protein Formulations
Garidel, P., & Presser, I. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-8928-7_12 · Cited by 24
Gabrielle, P., Nguyen, V., Wolff, B., Essex, R. W., Young, S. H., Hunt, A., Cheung, C. M. G., Arnold, J., Barthelmes, D., Creuzot-Garcher, C. P., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.06.020 · Cited by 19
Kiminami, H., Krueger, A. B., Abe, Y., Yoshino, K., & Carpenter, J. F. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.007 · Cited by 18
Self-citationDaka, Q., Špegel, N., Velkovska, M. A., Steblovnik, T., Kolko, M., Neziri, B., & Cvenkel, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144674 · Cited by 19
“Bevacizumab is thought to have an increased risk because it is drawn from a larger vial, usually in multiple syringes not designed for protein products, and frozen for a variable time compared to single-dose vials drawn into the syringe immediately before injection [50,55].”
BackgroundResultInfluentialWozniewski, M., Besheer, A., Sediq, A. S., Huwyler, J., Mahler, H., & Levet, V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.012 · Cited by 17
Selective separation method of aggregates from IgG solution by aqueous two-phase system
Shibata, C., Iwashita, K., & Shiraki, K. (2019) · Protein Expression and Purification · doi:10.1016/j.pep.2019.05.002 · Cited by 17
Subvisible Particles in IVIg Formulations Activate Complement in Human Serum
Chisholm, C. F., Behnke, W. D., Pokhilchuk, Y., Frazer‐Abel, A. A., & Randolph, T. W. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.041 · Cited by 17
Prevention and treatment of injection-related endophthalmitis
Yu, C. Q., & Ta, C. N. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2644-0 · Cited by 16
“Reports suggest problems with the quality and stability of compounded bevacizumab [24, 25].”
BackgroundFunke, S., Matilainen, J., Nalenz, H., Bechtold-Peters, K., Mahler, H., & Frieß, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.05.007 · Cited by 16
Long-term in vitro functional stability of compounded ranibizumab and aflibercept
Cao, S., Cui, J. Z., Matsubara, J. A., & Forooghian, F. (2017) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2016.11.012 · Cited by 15
Al-Abdullah, A. A., Nowilaty, S. R., Asghar, N., Al-Kharashi, A. S., & Ghazi, N. G. (2014) · Retina · doi:10.1097/iae.0000000000000371 · Cited by 15
“Based on these findings, Good et al and others proposed that transportation and storage of bevacizumab in plastic syringes coated with silicone may result in leashing of silicone particles into the drug solution that could, in turn, obstruct the TM after injection into the eye.(19) Another speculative mechanism for th…”
BackgroundSpini, A., Giometto, S., Donnini, S., Posarelli, M., Dotta, F., Ziche, M., Tosi, G. M., Girardi, A., Lucenteforte, E., Gini, R., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.015 · Cited by 14
Saggu, M., Bou-Assaf, G. M., Bucher, R., Budyak, I. L., Buecheler, J. W., Cao, S., Groenning, M., Khan, E., Kwok, S. C., Minocha, S., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.01.002 · Cited by 14
Metadata
- Authors
- Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F.
- Affiliations
- University of Colorado Denver (US)
- University of Colorado Anschutz (US)
- From the Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-02-22
- Volume
- 52
- Issue
- 2
- Pages
- 1023
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC3053093
- OpenAlex
- W2031531075
- Cited by
- 199
- References
- 21
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 10 · 2021: 25 · 2020: 16 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 10 · 2015: 10 · 2014: 15 · 2013: 14 · 2012: 19
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (R01EB006006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- bevacizumab, ranibizumab, compounding pharmacies, protein aggregates, subvisible particles, freeze-thaw cycles, drug storage conditions, plastic syringes
- MeSH terms
- Bevacizumab, Ranibizumab, Antibodies, Monoclonal, Drug Compounding, Drug Packaging, Drug Stability, Drug Storage, Particle Size, Silicone Oils, Angiogenesis Inhibitors, Particulate Matter, Protein Multimerization, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.